BSE Live
Nov 28, 12:48Prev. Close
1488.90
Open Price
1488.90
Bid Price (Qty.)
1447.05 (41)
Offer Price (Qty.)
1449.90 (8)
NSE Live
Nov 28, 12:48Prev. Close
1492.80
Open Price
1499.00
Bid Price (Qty.)
1447.20 (5)
Offer Price (Qty.)
1448.80 (6)
| Key Financial Ratios of Tatva Chintan Pharma Chem (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.14 | 12.82 | 18.26 | 44.65 | 25.57 | |
| Diluted EPS (Rs.) | 0.14 | 12.82 | 18.26 | 44.65 | 25.57 | |
| Cash EPS (Rs.) | 11.96 | 23.49 | 22.57 | 47.00 | 28.92 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 308.36 | 310.31 | 227.74 | 211.54 | 80.61 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 308.36 | 310.31 | 227.74 | 211.54 | 80.61 | |
| Dividend / Share(Rs.) | 1.00 | 2.00 | 2.00 | 2.00 | 5.00 | |
| Revenue from Operations/Share (Rs.) | 156.64 | 161.88 | 181.84 | 193.01 | 144.96 | |
| PBDIT/Share (Rs.) | 12.57 | 31.79 | 27.23 | 52.46 | 34.99 | |
| PBIT/Share (Rs.) | 0.75 | 20.85 | 22.92 | 48.77 | 31.64 | |
| PBT/Share (Rs.) | 0.20 | 18.07 | 17.52 | 46.59 | 29.54 | |
| Net Profit/Share (Rs.) | 0.14 | 12.55 | 18.26 | 43.31 | 25.57 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 8.02 | 19.64 | 14.97 | 27.17 | 24.13 | |
| PBIT Margin (%) | 0.47 | 12.87 | 12.60 | 25.26 | 21.82 | |
| PBT Margin (%) | 0.12 | 11.16 | 9.63 | 24.13 | 20.38 | |
| Net Profit Margin (%) | 0.08 | 7.75 | 10.03 | 22.43 | 17.63 | |
| Return on Networth / Equity (%) | 0.04 | 4.04 | 8.01 | 20.47 | 31.71 | |
| Return on Capital Employed (%) | 0.24 | 6.70 | 9.95 | 22.39 | 32.97 | |
| Return on Assets (%) | 0.03 | 3.60 | 5.36 | 14.71 | 16.58 | |
| Total Debt/Equity (X) | 0.05 | 0.02 | 0.34 | 0.26 | 0.47 | |
| Asset Turnover Ratio (%) | 0.45 | 0.48 | 0.57 | 0.89 | 1.05 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.51 | 3.37 | 1.27 | 2.53 | 1.53 | |
| Quick Ratio (X) | 1.28 | 1.71 | 0.65 | 1.58 | 0.94 | |
| Inventory Turnover Ratio (X) | 2.74 | 2.56 | 1.38 | 2.22 | 2.38 | |
| Dividend Payout Ratio (NP) (%) | 1,430.58 | 15.93 | 10.95 | 0.00 | 7.82 | |
| Dividend Payout Ratio (CP) (%) | 16.71 | 8.51 | 8.86 | 0.00 | 6.91 | |
| Earnings Retention Ratio (%) | -1,330.58 | 84.07 | 89.05 | 0.00 | 92.18 | |
| Cash Earnings Retention Ratio (%) | 83.29 | 91.49 | 91.14 | 0.00 | 93.09 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 1,612.66 | 2,502.58 | 3,826.36 | 5,060.21 | 0.00 | |
| EV/Net Operating Revenue (X) | 4.40 | 6.61 | 9.49 | 11.83 | 0.00 | |
| EV/EBITDA (X) | 54.84 | 33.65 | 63.40 | 43.52 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 4.33 | 6.67 | 9.17 | 11.96 | 0.00 | |
| Retention Ratios (%) | -1,330.58 | 84.06 | 89.04 | 0.00 | 92.17 | |
| Price/BV (X) | 2.20 | 3.48 | 7.32 | 10.91 | 0.00 | |
| Price/Net Operating Revenue | 4.33 | 6.67 | 9.17 | 11.96 | 0.00 | |
| Earnings Yield | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 |
24.11.2025
Reduce Tatva Chintan Pharma Chem; target of Rs 1380: Deven Choksey
10.11.2025
Tatva Chintan Standalone September 2025 Net Sales at Rs 115.86 crore, up 43.11% Y-o-Y
31.10.2025
Tatva Chintan Consolidated September 2025 Net Sales at Rs 123.52 crore, up 47.94% Y-o-Y
03.09.2025
Sell Tatva Chintan Pharma Chem; target of Rs 860: Deven Choksey
10.11.2025
Tatva Chintan Standalone September 2025 Net Sales at Rs 115.86 crore, up 43.11% Y-o-Y
31.10.2025
Tatva Chintan Consolidated September 2025 Net Sales at Rs 123.52 crore, up 47.94% Y-o-Y
25.07.2025
Tatva Chintan Consolidated June 2025 Net Sales at Rs 116.86 crore, up 10.81% Y-o-Y
25.07.2025
Tatva Chintan Standalone June 2025 Net Sales at Rs 109.18 crore, up 16.39% Y-o-Y